Patents Assigned to Biogen, Inc.
  • Patent number: 11192856
    Abstract: The invention relates to a novel process for preparing a-carboxamide pyrrolidine derivatives, in particular (2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide, and to novel intermediates for use in said process along with processes for preparing said intermediates.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: December 7, 2021
    Assignee: Biogen Inc.
    Inventors: Weirong Chen, Vinny Couming, Erwin Irdam, William F. Kiesman, Daw-Long A. Kwok, Tamera L. Mack, Suzanne M. Opalka, Daniel B. Patience, Donald G. Walker, Wenli Liang
  • Patent number: 11149039
    Abstract: The invention relates to a novel process for preparing Spiro derivatives, in particular 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one, and to novel intermediates for use in said process along with processes for preparing said intermediates.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: October 19, 2021
    Assignee: Biogen Inc.
    Inventors: Gerard M. Giblin, David T. MacPherson, Osama Suleiman, Michael Williams, David R. Witty, Thierry Bonnaud, Richard Edwards
  • Patent number: 10654940
    Abstract: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: May 19, 2020
    Assignees: Genentech, Inc., F. Hoffmann-La Roche AG, Biogen Inc.
    Inventors: Mark Totoritis, Timothy Mark Shaw, Sunil Agarwal, David Yocum, Ariella Kelman
  • Patent number: 10450379
    Abstract: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: October 22, 2019
    Assignees: Genetech, Inc., F. Hoffmann-La Roche AG, Biogen Inc.
    Inventors: Mark Totoritis, Timothy Mark Shaw, Sunil Agarwal, David Yocum, Ariella Kelman
  • Patent number: 10400043
    Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: September 3, 2019
    Assignee: Biogen, Inc.
    Inventors: Christine A. White, Antonio J. Grillo-Lopez
  • Patent number: 10113000
    Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: October 30, 2018
    Assignee: Biogen Inc.
    Inventor: Antonio J. Grillo-Lopez
  • Publication number: 20180264107
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: May 17, 2018
    Publication date: September 20, 2018
    Applicants: Genentech, Inc., Biogen Inc.
    Inventors: John G. Curd, Antonio J. Grillo-Lopez, Lori A. Kunkel
  • Publication number: 20170360890
    Abstract: The present invention provides a method for treating multiple sclerosis (MS), and for reducing flu-like symptoms associated with administration of an interferon to a patient with MS. The method involves intramuscularly administering the interferon to the MS patient according to an escalating dosing regimen in weeks 1 to 3, and a full therapeutically effective dose of interferon in week 4. In one embodiment of the invention, the escalating dosing regimen comprises administering one quarter of the therapeutically effective dose in week 1, half of the therapeutically effective dose in week 2, and three-quarters of the therapeutically effective dose in week 3. Also provided are titration packages for enabling compliance with a regimen of changing dosage of an interferon over a period of time.
    Type: Application
    Filed: September 5, 2017
    Publication date: December 21, 2017
    Applicant: Biogen Inc.
    Inventor: Aaron DEYKIN
  • Patent number: 9504744
    Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: November 29, 2016
    Assignee: Biogen Inc.
    Inventors: Christine A. White, Antonio J. Grillo-Lopez
  • Patent number: 9493567
    Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: November 15, 2016
    Assignee: Biogen Inc.
    Inventor: Ivan Lieberburg
  • Publication number: 20160175435
    Abstract: The present invention concerns treatment of pemphigus with an antibody which binds to CD20.
    Type: Application
    Filed: July 16, 2015
    Publication date: June 23, 2016
    Applicants: BIOGEN INC., GENENTECH, INC.
    Inventors: John G. Curd, Antonio J. Grillo-Lopez
  • Publication number: 20160101157
    Abstract: The present invention provides a method for treating multiple sclerosis (MS), and for reducing flu-like symptoms associated with administration of an interferon to a patient with MS. The method involves intramuscularly administering the interferon to the MS patient according to an escalating dosing regimen in weeks 1 to 3, and a full therapeutically effective dose of interferon in week 4. In one embodiment of the invention, the escalating dosing regimen comprises administering one quarter of the therapeutically effective dose in week 1, half of the therapeutically effective dose in week 2, and three-quarters of the therapeutically effective dose in week 3. Also provided are titration packages for enabling compliance with a regimen of changing dosage of an interferon over a period of time.
    Type: Application
    Filed: November 9, 2015
    Publication date: April 14, 2016
    Applicant: BIOGEN INC.
    Inventor: Aaron DEYKIN
  • Patent number: 9296821
    Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: March 29, 2016
    Assignee: Biogen Inc.
    Inventor: Antonio J. Grillo-López
  • Patent number: 9198955
    Abstract: The present invention provides a method for treating multiple sclerosis (MS), and for reducing flu-like symptoms associated with administration of an interferon to a patient with MS. The method involves intramuscularly administering the interferon to the MS patient according to an escalating dosing regimen in weeks 1 to 3, and a full therapeutically effective dose of interferon in week 4. In one embodiment of the invention, the escalating dosing regimen comprises administering one quarter of the therapeutically effective dose in week 1, half of the therapeutically effective dose in week 2, and three-quarters of the therapeutically effective dose in week 3. Also provided are titration packages for enabling compliance with a regimen of changing dosage of an interferon over a period of time.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: December 1, 2015
    Assignee: BIOGEN INC.
    Inventor: Aaron Deykin
  • Patent number: 8834906
    Abstract: Disclosed herein are a color capsule composition, which contains a polymer and a plasticizer swelling the polymer so as to allow the capsule particles to easily break and in which the capsule particles have a porous structure that boosts the effects thereof, and a method for preparing the color capsule composition. The preparation method comprises: uniformly mixing a color pigment, a plasticizer and a polymer in a first solvent to produce a first mixture solution; spray-drying the first mixture solution to produce core particles in which the color pigment is covered by the polymer; uniformly mixing the obtained core particles, a functional pigment and a second solvent to produce a second mixture solution; and spray-drying the second mixture solution to produce in which a coating layer of the functional pigment is formed on the outer surface of the polymer.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: September 16, 2014
    Assignee: Biogenics, Inc.
    Inventors: Chul-Hwan Kim, Tae-Sung Ko, Han-Joon Kim, Choa-Jin Kim, Jong-Hyun Choi, Chang-Hun Ji
  • Publication number: 20120258878
    Abstract: The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups by way of a multigene signature, comprising at least 5 genes from Table 3. The application also includes kits and computer products for use in the methods of the application.
    Type: Application
    Filed: August 4, 2011
    Publication date: October 11, 2012
    Applicant: Med Biogene Inc.
    Inventor: Fadia Saad
  • Publication number: 20100260761
    Abstract: The present invention relates to antibodies that bind Tumor Necrosis Factor Related Ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: June 5, 2006
    Publication date: October 14, 2010
    Applicants: BIOGEN, INC., THE FACULTY OF MEDICINE OF THE UNIV. OF GENEVA
    Inventors: Jeffrey Browning, Yves Chicheportiche
  • Patent number: 7255854
    Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: August 14, 2007
    Assignee: Biogen, Inc.
    Inventors: Jeffrey L. Browning, Paula S. Hochman, Paul D. Rennert, Fabienne Mackay
  • Publication number: 20070031920
    Abstract: High expression locus vectors based, in part, on the ferritin heavy chain locus are disclosed. The vectors include distal 5? flanking sequences and/or proximal 5? regulatory sequences derived from ferritin heavy chain locus. The vectors include a site for insertion of heterologous sequences and proximal 3? regulatory and distal 3+ flanking sequences. The proximal 3? regulatory and distal 3? flanking sequences are optionally derived from the ferritin heavy chain locus. Cells transformed with the vectors, and methods of producing heterologous proteins encoded by the vectors, are also disclosed.
    Type: Application
    Filed: October 22, 2003
    Publication date: February 8, 2007
    Applicant: BIOGEN, INC.
    Inventor: Holly Prentice
  • Patent number: 7173046
    Abstract: The present invention relates to novel CD40:CD154 binding interrupter compounds and use of these compounds and pharmaceutical compositions comprising them, to treat conditions associated with inappropriate CD154 activation in a subject. Specifically, this invention provides compounds which are identified by screening a library of small molecules for those that are capable of specifically binding CD154 and interrupting CD40:CD154 interaction.
    Type: Grant
    Filed: February 28, 2003
    Date of Patent: February 6, 2007
    Assignee: Biogen, Inc.
    Inventors: Zhongli Zheng, Mary-Beth Carter, YuSheng Liao, Lihong Sun, Leonid Kirkovsky, Susan Mrose, Yen-Ming Hsu, David Thomas, Gerald W. Shipps, Jr., Satish Jindal, George R. Lenz, Huw M. Nash